Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,755.20
(
-1.56%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
107.74
(
1.08%
)
Bitcoin
71,076.44
(
-0.21%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 125890

Tuesday, 08/30/2011 11:00:48 AM

Tuesday, August 30, 2011 11:00:48 AM

Post# of 257257
The existence of a proprietary patented process speaks to the “willfulness” (i.e. the lack thereof) of NVS/MNTA’s infringement in the event the Judge finds that NVS/MNTA’s generic Copaxone does infringe.

When was the last time treble damages were assessed in a generic-drug case? I’m not sure if it’s ever happened.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now